May
06
FDA approves AstraZeneca-POZEN arthritis drug
Filed Under (Main Content) by Content Keyword RSS
AstraZeneca and POZEN Inc. announced the U.S. Food and Drug Administration (FDA) approved VIMOVO delayed-release tablets for the relief of arthritis. The drug reduces the risk of getting gastric ulcers associated with taking some types of arthritis pain relief medicines.
May
05
FDA approves AstraZeneca-POZEN arthritis drug
Filed Under (Main Content) by Content Keyword RSS
AstraZeneca and POZEN Inc. announced the U.S. Food and Drug Administration (FDA) approved VIMOVO delayed-release tablets for the relief of arthritis. The drug reduces the risk of getting gastric ulcers associated with taking some types of arthritis pain relief medicines.
May
04
FDA approves AstraZeneca-POZEN arthritis drug
Filed Under (Main Content) by Content Keyword RSS
AstraZeneca and POZEN Inc. announced the U.S. Food and Drug Administration (FDA) approved VIMOVO delayed-release tablets for the relief of arthritis. The drug reduces the risk of getting gastric ulcers associated with taking some types of arthritis pain relief medicines.
May
03
FDA OKs Astrazeneca-Pozen arthritis relief drug
Filed Under (Main Content) by Content Keyword RSS
AstraZeneca and POZEN Inc. announced the U.S. Food and Drug Administration (FDA) approved VIMOVO delayed-release tablets for the relief of arthritis. The drug reduces the risk of getting gastric ulcers associated with taking some types of arthritis pain relief medicines.
May
03
FDA approves AstraZeneca-POZEN arthritis drug
Filed Under (Main Content) by Content Keyword RSS
AstraZeneca and POZEN Inc. announced the U.S. Food and Drug Administration (FDA) approved VIMOVO delayed-release tablets for the relief of arthritis. The drug reduces the risk of getting gastric ulcers associated with taking some types of arthritis pain relief medicines.